Effects of GSK1070806 (anti-IL18 mAb) on biomarkers in synovial tissue and blood of patients with rheumatoid arthritis.

GSK1070806（抗 IL18 mAb）对类风湿关节炎患者滑膜组织和血液中生物标志物的影响。

• 批准号: MR/Y020464/1
• 负责人: Aurelie Najm
• 金额: $ 108.78万
• 依托单位: University of Glasgow
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY020464%2F1
• 关键词: Effects; GSK1070806; anti; IL18; mAb

Although the introduction of novel therapies has greatly improved the outlook for patients with rheumatoid arthritis over the years, considerable unmet needs remain. This work will evaluate a potential new mode of action that could be used in early or established rheumatoid arthritis to halt the progression of disease. We will evaluate changes in inflammation observed in the synovial tissue (the membrane around the joint, target of inflammation in arthritis) induced by GSK1070806, a new drug targeting a messenger of inflammation present in the joint. 13 patients will be recruited across 3 centers. Our exploratory objectives will study changes in synovial inflammation evaluated by a range of cutting edge methodologies. Safety and tolerance will also be assessed.

尽管多年来新疗法的引入极大地改善了类风湿性关节炎患者的前景，但仍有相当大的需求未得到满足。这项工作将评估一种潜在的新的作用模式，可以用于早期或确诊的类风湿性关节炎，以阻止疾病的进展。我们将评估GSK1070806引起的滑膜组织(关节周围的膜，关节炎炎症的靶标)中观察到的炎症变化，GSK1070806是一种针对关节中存在的炎症信使的新药。将在3个中心招募13名患者。我们的探索性目标将研究滑膜炎症的变化，通过一系列尖端方法进行评估。还将评估安全性和耐受性。